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REVIEW

Role of ATG16L , NOD2 and IL23R in Crohn’s disease
pathogenesis
Saleh A Naser, Melissa Arce, Anam Khaja, Marlene Fernandez, Najih Naser, Sammer Elwasila,
Saisathya Thanigachalam
key in acquiring CD. Many studies have proven the link
between mutations in the ATG16L , NOD2/CARD15 ,
IBD5 , CTLA4 , TNFSF15 and IL23R genes, and CD. The
purpose of this review is to examine all genetic aspects
and theories of CD, including up to date multiple popu�
lation studies performed worldwide.
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Abstract
Inflammatory bowel disease is a group of diseases that
includes Crohn’s disease (CD) and ulcerative colitis. CD
is characterized as a chronic inflammatory disease of
the gastrointestinal tract, ranging from the mouth to
the anus. Although there are gross pathological and
histological similarities between CD and Johne’s dis�
ease of cattle, the cause of CD remains controversial.
It is vital to understand fully the cause of this disease
because it affects approximately 500 000 people in
North America and Europe. It ranges from 27 to 48
cases per 100 000 people. There are many theories
on the cause of CD ranging from possible association
with environmental factors including microorganisms
to imbalance in the intestinal normal flora of the pa�
tients. Regardless of the environmental trigger, there
is strong evidence that a genetic disposition is a major
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INTRODUCTION
The first description of Crohn’s disease (CD) was made
in 1769 by an Italian physician, Giovanni Battista Morgagni, when he diagnosed a man with chronic diarrhea.
In 1898, consecutive cases were reported by John Berg,
and then in 1904 by Antoni Lesniowski. Throughout the
1920s and 1930s, young adults were thought to have this
same condition as they suffered from symptoms, such as
abdominal cramps, diarrhea, fever and significant weight
loss. In 1923, surgeons at Mt. Sinai Hospital in New
York had also identified patients with comparable symptoms. In addition, in 1930, Dr. Burrill B Crohn saw a
connection between this unknown debilitating condition
and two of his patients. Consequently, Dr. Crohn and his
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colleagues presented a paper in 1932, “Regional ileitis: a
pathologic and chronic entity”, describing the features
of this disease to the American Medical Association. CD
was named after Burrill Crohn and it became an official
medical entity in 1932.
CD is a chronic inflammatory disease that can affect
any portion of the digestive tract including the mouth,
esophagus, and small and large intestines, but is most
common in the ileum. It is also characterized as an autoimmune disease in which the body attacks itself and
causes inflammation. In its mild form, it causes erosions
called aphthous ulcers in the inner surface of the bowel.
In severe cases, deeper and larger ulcers develop that can
lead to bowel obstruction and holes in the bowel wall. If
a hole in the bowel wall arises, infection to neighboring
organs can occur. CD branches off to many forms depending on the location of erosion. If these symptoms
take place within the large intestine, it is called Crohn’s or
granulomatous colitis. If it occurs in the small intestine,
it is known as Crohn’s enteritis, and more specifically if
it occurs in the ileum, it is called Crohn’s ileitis. During
severe cases in which the small and large intestine are
both involved, it is known as Crohn’s enterocolitis or
ileocolitis. CD is separated into three phenotypes: nonstricturing and non-penetrating, stricturing and penetrating CD[1,2].
CD is most prevalent in North America and Europe,
and least prevalent among African Americans and Asians[3].
It affects approximately 500 000 people in North America
and Europe. It ranges from 27 to 48 cases per 100 000
people. There is no difference in prevalence among males
or females. Individuals with siblings affected by CD have
a higher risk of acquiring the disease. There is evidence
of a cause from environmental factors, thus, there are a
higher number of cases in western industrialized countries.
Symptoms of CD typically begin in the teens and twenties
and then go into remission on and off with appropriate
therapies. There is a peak incidence between 50 years and
70 years of age, which often leads to major complications
due to age and the necessity of surgery.
Although the etiology is still unknown, there are
many theories about what causes CD and ulcerative
colitis (UC). Many believe it is caused by environmental
factors, such as certain foods, bacteria, viruses, or cigarette smoke, which all can trigger an immune system
response. Scientists have linked inflammatory bowel
diseases (IBDs) as an autoimmune problem. In a healthy
person, the immune system defends the body against
harmful microbes that have entered it. Upon triggering
the immune system, an inflammatory response occurs
in which immune cells aggregate at the site of infection
and overcome the threat. There are microbes native to
our bodies that are useful rather than harmful to which
the immune system does not trigger a response. In patients with CD, the immune system will attack these native luminal bacteria, disrupting the normal flora, thus
characterizing this condition as an autoimmune disease.
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Recent research has indicated specific genetic variations as a direct cause of CD and UC. The genetic aspects
of CD have been linked by observing familial clustering of IBD cases[4]. Genetic variations in the ATG16L,
NOD2/CARD15 and IL23R genes have strongly been
linked to the onset of CD[5]. Not only are individual gene
mutations listed as a cause of CD, but a combination of
them has also been shown in CD patients by conducting many population studies. There have also been many
studies that have predicted surgical outcomes in both
adults and children with specific genetic variations.
Diagnosis of CD can be tricky and requires a number of tests to be certain. Colonoscopy is the most effective way to diagnose CD but not in all cases because
it only allows the physician to visualize the colon, ileum,
and lower portion of the small intestine[6]. If the ulcers are located within the upper portion of the small
intestine, this test will not be effective. In this case, a
barium follow-through X-ray is useful because barium
sulfate gives fluoroscopic images of the bowel and the
physician can see areas of inflammation and narrowing[6]. Another effective method of diagnosis is the use
of white blood cell scans. During this procedure, white
blood cells are tagged with a radioisotope and then
injected back into the patient. At specific intervals of
time, the scan can locate accumulations of white blood
cells in the intestine at the site of CD. This method is
also useful to monitor the disease and show effectiveness in other therapies. Furthermore, a simple blood
test can also diagnose CD because it can determine
whether the patient is anemic or has a vitamin B12 deficiency because vitamin B12 is absorbed in the ileum and
a deficiency can be due to ileitis.
CD causes a wide variety of symptoms and can be
confused with UC, which is a similar disease, both under
the group of IBDs. UC is only found in the colon and
affects the mucosal membrane, whereas CD can occur
anywhere throughout the gastrointestinal (GI) tract and
affects the thickness of the GI wall. Individuals with CD
can experience flare-ups followed by remissions. It can
vary from one flare-up in a lifetime to multiple flare-ups
that need surgical treatment. Symptoms include persistent diarrhea, abdominal pain in the affected area, fever,
and weight loss[6]. There are also signs and symptoms
that may occur unrelated to the GI tract, such as reddening and inflammation of the eye, joint pain, skin lesions,
and sores inside the mouth.
Currently, there is no cure for CD. Treatment is focused on relieving the symptoms and putting it into remission. Since CD is characterized as an autoimmune disease, medications to suppress the immune system include
5-aminosalicylic acid and steroids, such as prednisone[6].
Antibiotics such as clarithromycin, ampicillin and metronidazole, can also be used. More than 50% of patients with
CD will have to undergo surgical treatment to correct
a fistula, drain an abscess, open a narrow or obstructed
bowel, or remove a segment of infected intestine.
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ond report from the North American CD genome-wide
study submitted by Rioux and colleagues also shows an
association with ATG16L using a case-control analysis
in 988 CD patients and 1007 controls[11]. Another group
of German and British collaborators demonstrated that
rs2241880, another non-synonymous variant of the
ATG16L gene on chromosome 2q37.1, is implicated in
the autophagy pathway[8].
In a study performed on an Italian cohort, the same
polymorphism, rs2241880, was observed in 667 CD and
668 UC patients[12]. Both the frequency of the G allele
and number of carriers of the G allele were increased
in CD patients when compared to the controls[12]. These
differences were only significant in the adult subgroup,
which could be due to the small sample size of the pediatric subgroup. In comparison, there were no significant allele or genotype frequencies found between UC
patients and controls for the groups as a whole[12]. During analysis of genotype/phenotype correlation of the
rs2241880 SNP, there were no associations with disease
location, behavior, and age at diagnosis based on the
Montreal Classification of CD[12]. There were also no associations found in sex, smoking, and perianal fistulae[12].
For the rs2241880 variant, recent studies, specifically
by Prescott[13], demonstrate an association with the ileal
form of CD with or without colonic involvement, but
not with isolated colonic disease[12].
In addition, a study from Oxford compared 645 CD
patients with 1190 controls and showed an association of ATG16L1 with CD [14] . To understand fully
the function of this gene, a study utilized oligo-based
silencing RNA directed against ATG16L1 isoforms,
where autophagy was induced by Salmonella typhimurium
in ATG16L1 knockdown HEK293 cells. There was a
significant difference between the knockdown cells
com-pared to the control cells during the autophagy pathway[11]. It is clear to say that variants of this gene have
been proven without a doubt to be directly associated
with CD because autophagy plays a critical role in disease pathogenesis. Further research needs to focus on
understanding how ATG16L1 variants contribute to
disease susceptibility in IBD patients, and their possible
therapeutic implications.

AUTOPHAGY-RELATED 16-LIKE 1
PROTEIN COMPLEX
Autophagy is a catabolic process of intracellular degradation in which cytoplasmic components are sequestered
within vesicles and delivered to the lysosomes. Cells use
this pathway during nutrient starvation because they
can break down non-vital components and use them
as nutrients. Autophagy plays a role during infection by
helping rid the cell of foreign antigens by breakdown of
the pathogen. This pathway can also be implemented as
a repair mechanism to degrade damaged organelles and
proteins. Autophagosomes, formed by the fusion of lysosomes and vesicles, are also implicated in the processing of intracellular bacteria. If the gene responsible for
autophagy is mutated, it can cause a shift in normal flora
as previously mentioned, and lead to many GI problems,
which has been pointed out as a possible cause of CD.
If the cell cannot regain nutrients or fight off foreign
antigens within the GI tract, these cells will undergo
programmed cell death and cause tissue damage. This
damage can be seen as lesions and ulcers within the intestines, creating dead infected patches of tissue along
the GI tract. The only option of treatment is surgery to
remove the sections of the intestines with the diseased
tissue so that the necrosis will not spread among neighboring cells.
An autophagosome, a double-membraned vesicle
formed by autophagy, envelops part of the cytoplasm
and delivers it to the lysosomes where it is degraded and
recycled. There have been approximately 30 autophagyrelated (Atg) genes identified, with two proteins having
ubiquitin-like characteristics, Atg12 and Atg8[7]. These
proteins covalently modify their target protein with
molecules such as ubiquitin-like proteins to tag them
for degradation. Both proteins also contain a conserved
ubiquitin-fold region[7]. Autophagosomes use two conjugation systems, the Atg12 and LC3-Ⅱ systems [8] .
These systems were first discovered during yeast genetic
studies revealing a set of 17 ATG genes involved in the
autophagy pathway[9]. In the Atg12 conjugation system,
an Atg12-Atg5-Atg16L complex forms, and dissociates
from the membrane just before or after completion
of the autophagosome[8]. The ATG16L1 protein is expressed in the colon, small intestine, intestinal epithelial
cells, leukocytes, and spleen[8]. Recent independent studies have shown that an ATG16L mutation, located on
chromosome 2, is associated with the onset of ileal CD,
and is therefore a key molecule in elucidating the genetic
aspects of this disease[10].
Multiple studies have been performed with each resulting in the same conclusion that ATG16L is implicated in CD. During a genome-wide survey of 19 779 nonsynonymous single nucleotide polymorphisms (SNPs),
Thr300Ala within the N terminus of ATG16L was
found to be highly associated with CD by using a haplotype and regression analysis[4]. This study used a total
of 735 CD patients, 368 controls and 72 SNPs. A sec-
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TUMOR NECROSIS FACTOR SUPER
FAMILY 15
Tumor necrosis factor super family 15 (TNFSF15) is a
Th-1 polarizing cytokine involved in systemic inflammation. TNF functions to regulate immune cells, induce
apoptosis, induce inflammation, and inhibit tumorigenesis. TNFs are produced by macrophages, lymphoid
cells, mast cells and endothelial cells. During immunological studies, it has been found that CD patients have
an increased expression of TNFSF by multiple cells in
the intestinal tissues when compared to controls[7]. The
TNFSF15 gene is a candidate for increased susceptibility
in IBD. It binds to a specific T-cell receptor to enhance
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cytokine-induced interferon expression in mucosal CD4+
T cells[7].
In 2005, the first genome study involving IBD tested
nearly 80 000 SNPs in Japanese CD patients. This study
identified haplotypes within the TNFSF15 gene, which
included seven SNPs within a 280-kb region on chromosome 9q32[15]. By resequencing TNFSF15 from the
same CD cases but with a new control group, TNFSF15
was found to be strongly associated with CD with an
odds ratio (OR) of 2.17 (95% CI: 1.78-2.66), P = 1.71 ×
10-14[15]. The Japanese wanted to see if the same patterns
were seen in other population groups so they replicated
their associate in two panels from Oxford, United Kingdom. Although the risk haplotype was identified in both
cohorts, there was a weaker effect size (P = 0.02 in both
family-based and case-control association panels). In
addition, another study involving a Jewish cohort also
showed an association of TNFSF15 with CD, and also
suggested that in response to FC-gamma receptor stimulation, TNFSF15 gene variation aggravates induction of
TNFSF15[16]. However, in a separate study using a Belgian CD cohort, no significant association was observed
between CD and TNFSF15[4]. This may have been due
to different marker genotypes or differences in susceptibility genes between Asian and European cohorts[4].
Not enough studies have been performed regarding
TNFSF15 and its possible implications in CD. Future
studies have to focus on different populations to provide
efficient insight.

The intestinal mucosa is constantly exposed to a large
number of commensal microorganisms; the majority of
which inhabit the large intestine. In a healthy individual,
there is a basal immune response elicited from the interaction between the intestinal immune system and
commensal bacteria. This immune response is constantly
present to protect the host from pathogenic and nonpathogenic bacteria. When there are changes within this
balance, the intestines are susceptible to chronic intestinal inflammatory conditions, such as CD[21]. Multiple
genetic studies have linked NOD2 with susceptibility
to CD. However, NOD2-deficient mice do not develop
colitis, suggesting that dysregulation of the NOD2
pathway is not sufficient to provoke CD[22]. This is not
a surprise because the pathogenesis of CD is caused by
several factors including environmental, dysfunctional
immune system, and a shift in normal bacterial flora[21].
NOD2 is expressed in Paneth cells, which are found
in the intestines. The exact functions of Paneth cells are
still unknown, but they are likely to contribute to the
host defense by secreting antibacterial compounds due
to the presence of lysozyme. A NOD2 mutation can
alter the function of Paneth cells, which alters their antimicrobial activity and leads to the development of ileal
lesions, which correspond to the location of these cells.
Of the three NOD2 mutations associated with CD, both
rs2066844 and rs2066845 are the result of a two-aminoacid substitution in which rs2066844 is encoded by exon
4 and rs2066845 is encoded by exon 8[23]. The variant
1007fs is created by a frameshift mutation in exon 11[23].
Each of the three mutations occurs within or near the
leucine-rich repeat and decrease the cells ability to activate NF-κB in response to peptidoglycan[18]. Interestingly, these mutations are observed in Caucasian patients
but not in Japanese, Chinese and Korean patients with
IBD, and they are very rare in African Americans with
IBD[24,25]. An individual heterozygous for at least one
NOD2 mutation is at a 2-4-fold increased risk of developing CD, whereas a homozygous individual for at least
one NOD2 mutation is at a 20-40-fold increased risk
when compared to healthy individuals[14].
Studies of each individual mutation in NOD2 have
shown that 1007fs causes a decrease in defensin expression[26]. Defensins are cells of the immune system that
assist in killing phagocytized bacteria. They function by
binding to the microbial cell membrane and forming
a pore in the membrane that allows outward flow of
nutrients and essential ions. CD patients who are homozygous and/or heterozygous for NOD2 mutations typically have lower defensin levels in their ileostomy fluid[17].
As a result of a mutation in NOD2, the function of this
protein is diminished, therefore allowing subsequent
entry of bacteria into epithelial cells because they are
no longer able to recognize them. This in turn alters the
bacterial population in the intestines and thus, defensins
are not able to function correctly because they are working in an impaired bactericidal capacity[22].
In a recent study by Van Limbergen et al[17], it was

NOD2/CARD15 GENE
Nucleotide-binding oligomerization domain containing
2 (NOD2), located on chromosome 16q12, is a protein
that plays an essential role in the immune system by
controlling commensal bacterial flora in the intestine[17].
NOD2 belongs to a nucleotide-binding domain, leucinerich repeat family of cytoplasmic proteins that may
detect a variety of bacteria by acting as an intracellular
sensor for bacterial peptidoglycan[18]. It has the ability to
respond to N-acetylmuramyl-L-alanyl-D-isoglutamine
(MDP) via the leucine-rich repeat domain. The MDP is
conserved in both Gram-negative and positive bacteria[10,19]. This leucine-rich repeat domain plays a role in
protein-protein interactions and the middle portion of
the protein is responsible for self-oligomerization. The
N-terminal portion of NOD2 contains two caspase recruitment domains (CARDs) which play a role in apoptosis. The CARD15 gene, which encodes for the CARD
domain within NOD2, has been specifically identified
as a genetic factor for CD. Three SNPs were found
to be independently associated with CD: rs2066844,
rs2066845, and an insertion mutation 3020insC[20]. Each
variant may result in distinct phenotypic expression of
CD[4]. To activate NOD2, Rip2 kinase is required because it is necessary for downstream signaling of NOD2
and signaling cascades such as nuclear factor (NF)-κB
and mitogen-activated protein kinase cascades[21].
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proven that NOD2 is required for the regulation of
commensal microbiota in the intestine. The regulation
of NOD2 depends on the downstream kinase Rip2 because Rip2-deficient mice fail to establish and regulate
commensal bacteria in their terminal ileum. NOD2-deficient mice do not develop spontaneous intestinal inflammation. In conclusion, the NOD2–Rip2 pathway is critical for the regulation of homeostasis between the body’s
normal bacterial flora and innate immunity[17]. As a controlled balance, it has been found that the expression of
NOD2 and Rip2 is dependent upon and regulated by the
presence of commensal bacteria[17]. This creates a negative feedback by which the commensal bacteria positively
regulate NOD2, and in turn negatively regulate the normal flora. NOD2 mutations directly affect the ileum in
CD patients, thus, it is possible that they are responsible
for the composition of the bacterial flora in the terminal
ileum[17]. This may facilitate both disease pathology and
progression.
Although the exact mechanism by which NOD2 contributes to the control of commensals in the intestines
is still not known, there are many possible theories proposed by this study. The first theory entertains the possibility that NOD2 regulates the commensal flora through
the bactericidal activity of ileal crypt secretions[17]. The
second theory is that NOD2 regulates the adaptive immune system by inducing lymphoid tissue genesis[17].
The third theory describes how NOD2 expression in
myeloid lineage cells contributes indirectly to maintain
the normal microbiota flora[17]. The fourth theory states
that there may be other cells in the intestines, in addition
to Paneth cells, that may play a role in the regulation of
commensal bacteria in the intestines[17]. Further research
is needed to elucidate this mechanism.
It has been reported that both adults and pediatric
cohorts share a strong association between the NOD2
variants and ileal disease location[23]. Some studies have
suggested that adult patients show a correlation in fibrostenotic behavior and NOD2 mutation status, whereas
other studies have failed to replicate the same phenotypic
effect[12]. It is necessary to study different CD cohorts
from different countries to obtain an accurate effect of
each mutation. Exploring the genotype-phenotype interactions in children is beneficial because they show a higher gene dosage and have less environmental influences.
A study by Lacher and colleagues has explored the
association of the NOD2 mutation in German pediatric
CD patients and the risk of surgery. The risk of surgery in children is important to predict because surgery
is sometimes the only method of treatment. Out of
171 young CD patients, 78 (45.6%) carried at least one
NOD2 mutation, with 11 being compound heterozygous, and 14 being homozygous for two NOD2 mutations[14]. The presence of rs2066844 was found in 29
(17%) children, rs2066845 was found in 18 (10.5%), and
1007fs was found in 42 (24.6%)[14]. Overall, one out of
three German children with CD had at least one NOD2
mutation. In comparison, 36% of adult CD patients
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were heterozygous for at least one NOD2 mutation:
17.2% for rs2066844, 9.6% for rs2066845, and 11.7%
for 1007fs[14]. In conclusion, the genetic alterations were
observed more predominantly in German pediatric CD
patients than in adults. The study also looked into each
mutation and its association with localization and symptoms of the disease. A 4.73-fold increased risk of isolated ileal localization was observed in patients that were
identified as 1007fs carriers when compared to children
with none of the NOD2 mutations [14]. Although the
1007fs carriers were predisposed to ileal disease, there
was no involvement of the ileocolonic or upper GI
tract[14]. The next characterization the study explored
was the association of NOD2 mutations and stricturing disease or perianal fistulae in their German pediatric
CD cohort. Only 17% of patients showed a stricturing
phenotype and 18.1% had a perianal fistula[14]. Among
the children that showed a stricturing phenotype, 79.3%
required surgery and those with the 1007fs mutation had
surgical complications[14]. The outcome showed a 9.8-fold
increase in surgical complications when the child carried
at least one allele for the 1007fs mutation[14]. Not only
is the 1007fs mutation strongly associated with isolated
ileal disease, but children are at a high risk for surgical
intervention. Therefore, this mutation can act as a prognostic tool in Caucasian children with CD[14].
Another study by Jurgens and colleagues has investigated the presence of fistulas and their association with
NOD2 homozygosity and how they predict intestinal
stenosis in CD patients. It was observed that patients
with fistulas had simultaneous intestinal stenosis[15]. In
another study using the same research, it was found that
NOD2/CARD15 variants, especially with 1007fs homozygosity, could predict the occurrence of intestinal
stenosis[27]. By using a strict screening process based on
phenotypes including stenoses (stricturing CD) and fistulae (penetrating CD), and genotype, the study isolated
a total of 145 patients. One hundred and twenty-five
of the patients had penetrating CD with simultaneous
stenosis within a 6-mo interval [28]. It was also found
that all 14 CD patients homozygous for NOD2 variants suffered from stenosis[28]. To no one’s surprise, 11
out of the 14 patients with stenosis and fistulas carried
the NOD2 1007fs mutation[28]. These data confirm the
strong risk factor of the 1007fs NOD2 mutation in the
prevalence of intestinal stenosis, which may be related
to the decreased intestinal barrier function found in CD
patients with NOD2/CARD15 variant mutations [28].
This study has isolated the 1007fs variant as the cause
in disrupting the intestinal barrier and causing the many
problems often observed in CD patients.
To investigate whether stenosis occurs in a specific
anatomical region, 223 patients with 248 stenoses located
at different intestinal regions were examined[28]. The most
common anatomical region was the terminal ileum with
68.8% of stenoses, followed by 11.7% found in the rectosigmoidal segment, and 9.3% in the jejunum or proximal
ileum[28]. In conclusion, homozygosity in the NOD2/
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CARD15 mutation is a strong risk factor for intestinal
stenosis[28]. When the study looked into the possible association between stenosis and interleukin-23 receptor (IL23R mutation variants, there was a weak connection with
no influence on stenosis[28]. This study suggests classifying
CD into four disease phenotypes instead of the current
three in the Montreal Classification System. The four new
classifications would be: non-stricturing[12], non-fistulizing
CD[12]; stricturing, non-fistulizing CD[18]; non-stricturing,
fistulizing CD[29]; and stricturing, fistulizing CD[28]. It is
important to link any possible association between fistulas
and stenoses because there is a strong risk factor for recurrence of CD after surgery[28].
Many studies have investigated North American, European and Asian countries and their CD patients with
specific genotypes. Interestingly, the NOD2/CARD15
mutations are very rare and even absent in Asians (Japanese, Chinese and Korean), Arabs, Africans and African
Americans[28]. A study by Baptista and colleagues has
concentrated on a South American population for the
first time. There were a total of 187 CD patients used
for the study with a median age of 33 years and a median age of onset of 23 years[24]. Their patients were
ethnically classified into the following groups: 58.8%
were in the Brazilian subgroup, 36.9% shared a common
European ancestry and were in the European-Brazilian
subgroup, three were Amerindian-Brazilian, and two
were Afro-Brazilian[24]. The alleles related to CD within
the CARD15, rs2066844 and 3020insC variants were
significant for CD susceptibility[24]. Both the rs2066845
and 1007fs variants failed to show any significant association [24]. Among their patients, 30% had at least
one NOD2/CARD15 variant allele[24]. The frequency
of rs2066844 (9.63%) in the Brazilian CD cohort was
consistent with the reports for European populations[24].
In conclusion, this study confirmed that CARD15 variants lead to greater susceptibility to CD in the Brazilian
population[24].

Th-17 lymphocytes are a distinct subset of T-helper
cells, which mainly produce IL-17 and to a lesser extent
IL-6 and TNF-α[26]. IL-17 in vitro and in vivo acts as a
potent inflammatory cytokine and is involved in the destruction of cartilage and bone, as seen in rheumatoid
arthritis[12]. It has been reported that IL-23 could be a
key regulator in the differentiation of Th-17 lymphocytes from memory T cells. It also has been suggested
that IL-23 plays a role in providing a survival advantage
to already differentiated Th-17 cells[21]. The expression
of the heterodimeric receptor complex, IL-23R and IL12Rβ1, regulates activities of IL-23[12]. Therefore, the
IL-23-IL17 cytokine axis is a key pathogenic mechanism
that mediates the development and progress of inflammation by Th-17 cells. The role for the IL23-IL17 axis
in CD patients was supported in human patients and
animal models of colitis[31]. Both cytokines are increased
in knockout mouse models of IBD. More specifically,
IL-17 levels are increased in both intestinal mucosa and
in the serum of CD patients[12]. In a study using IL17R knockout mouse models, an association was found
with colitis and disease severity[27]. Therefore, the use of
anti-IL-12p40 antibody to treat CD patients is a therapeutic option because it is known to reduce production
of IL-23 and IL-17 in the lamina propria cells[12]. The
mechanism of IL-23R is clearly important to understand
because it is directly associated with CD.
During a genome-wide association study, 2877 DNA
samples from IBD patients (two-thirds CD and onethird UC), identified rs11209026 as a possible protective
variant, in the IL23 gene on chromosome 1p31[4]. There
are many other variants within IL23R that are associated
with IBD, but rs11209026 has the strongest association
with conferring protection against CD[4]. Although the
effect of IL23R variants is greatest in CD, it may have
an overall effect on susceptibility to chronic intestinal
inflammation.
Additional studies have confirmed the susceptibility
of the IL23R gene to CD in North American and European populations. They include cohorts ranging from
Scottish pediatric IBD, Belgian CD and an independent
cohort of 883 families[4]. Due to the role of IL-23 in activation of inflammatory responses, targeting this pathway may be a good therapeutic approach. Some promising research is underway using anti-p40, which blocks
IL-23 and IL-12 activities. The variant allele, rs11209026,
could be exploited to define clinical outcomes, such as
a pharmacological approach to mimic the rs11209026
polymorphism[4].
A study by Schmechel and colleagues has shown
a link in susceptibility to CD with Th17 cell function,
IL-22 serum levels, and IL23R genotype. IL-22 is a
strong activator of proinflammatory gene expression and
upregulates SOC3 mRNA in intestinal epithelial cells[29].
Recent evidence has shown that Th17 cells expressing
IL23R play a key role in the mechanism by which IL23R
modulates IBD susceptibility[32]. Previous studies have
shown that Th17 plays a role in autoimmune diseases,

INTERLEUKIN-23 RECEPTOR
IL-23R is a protein consisting of an IL-12β1 and an IL23R chain[27]. The molecular location of the IL23R gene
is on chromosome 1 and is formed by the binding of IL12p40 and a p19 protein[30]. It is highly expressed on the
cell membrane of memory T cells and other immune
cells, such as natural killer cells, monocytes, and dendritic
cells, which identify foreign substances to defend the
body against infection. It is highly involved in the mediation of proinflammatory activities by the production of
IL-17 via the activation of Th17 lymphocytes[20]. IL-23R
interacts with IL-23, which is a cytokine that regulates the
activity of immune cells and plays an important role in
the inflammatory response against infection by bacteria
and viruses. It also has been suggested that the functional
IL23R pathway polymorphisms play a role in modulating
neonatal development of intestinal tolerance and bacterial colonization[4].
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the negative association between rs11209026 and CD[35].
Another way to confirm the association of alleles
with CD and UC is to use a population that is genetically isolated, such as the Finnish population. This will
provide an advantage in molecular genetic studies in
complex disorders[36]. A study by Lappalainen has used
such a strategy to confirm the association of IL23R,
TNFRSF1A, and the HLA-DRB1*0103 allele variants.
The strongest association of IL23R with the marker
rs2201841 (IL-23R risk variant) showed a frequency
of 37.2% in CD. In most studies, the non-synonymous
SNP, rs11209026 (the protective IL23R allele), has had
the highest association, but is only marginally associated
with Finnish CD[36]. No association has been observed
between the IL23R markers and UC patients[36].
Previous studies have shown that the HLA-DRB1*0103
allele is associated with both UC and CD. In the Finnish
population, this allele only has a frequency of 0.6%, which
is not statistically significant, whereas it is significant
for UC and IBD[36]. When looking into the genotypephenotype association, patients carrying the rare HLADRB1*0103 allele have colonic involvement in CD[36].
During the TNFRSF1A analysis, the investigators genotyped a rare A36G variant and an IVS6+10A (rs1800693)
variant. CD patients with both variants often show
ileocolonic disease in comparison with patients without
these two variants[36]. The weak association is probably
due to the small sample size. Interestingly, when the
protective haplotype of IL-23R (described in the above
paragraph) was sequenced and compared to North
American Caucasian CD patients, there was a one-nucleotide difference between Finnish (CCTGATCG) and
North American (CGTGATCG) CD patients[36]. In conclusion, the HLA-DRB1*0103 allele has been confirmed
in CD patients, which shows an inherited susceptibility
of colonic inflammation. The TNFRSF1A gene variants are markers of ileocolonic involvement in CD[36].
Although this study shows a weaker association of the
IL23R gene, it confirms the genetic involvement within
a Finnish population.
In another population study among French-Canadian
and English-Canadian children, the association between
genetic variants of the IL23R gene and early-onset of
CD has been investigated. To study the associations accurately, they have carried out both a case-control and a
family-based study. They have targeted the 10 SNPs in
IL23R achieved by the genome-wide study and the three
CARD15 SNPs. In total, 259 CD patients and 139 controls were recruited with a mean age at diagnosis of 13.3
years (range: 2.6-20 years)[12]. The IL23R protective allele,
rs11209026, was only present in 2% of CD case chromosomes and 6% of the control chromosomes[12]. All
CARD15 variant allele frequencies were higher among
CD patients when compared to the control group[12]. In
the IL23R gene, they observed a significant association
among four SNPs that did not posses any CARD15 variants[12]. Therefore, variants in the IL23R gene were associated with early-onset CD among Canadian children.

such as rheumatoid arthritis and CD. However, Th17 is
responsible for the important function of antimicrobial
immunity at epithelial barriers where it produces cytokines such as IL-22. Because it produces IL-22 in epithelial barriers such as in the intestines, theoretically by
testing for increased IL-22 serum levels, a physician can
determine CD and disease activity.
It has been confirmed that IL-22 serum level is increased in CD and correlates with disease activity[33].
IL-22 serum levels are also independent of CD phenotype and CARD15 genotype, but are modulated by
IL23R polymorphisms[33]. The study investigated IL-17
serum because Th17 cells also produce IL-17. There was
no correlation between IL-22 and IL-17 serum levels[33].
Currently, serum levels of TNF-α and IL-6 are used as
inflammation markers in determining CD. There was
no difference in TNF-α and IL-6 levels whether CD
was active or in remission, whereas IL-22 levels were
significantly higher in active CD compared to CD in
remission[33]. Therefore, measuring IL-22 levels are clinically relevant in determining the disease activity in CD
patients[33].
There are also strong associations between IL-22
serum levels and IL23R gene variants. Previous studies have shown both protective and inducing variants
of IL23R in susceptibility to CD. Although rs1004819
is the CD increasing variant of IL23R, rs11209026 has
shown to be a protective IL23R variant against CD.
As predicted, when the IL-22 mean serum levels were
tested against each variant, the serum levels were highest
among SNPs that increased CD risk as opposed to the
identified protective SNPs of IL23R, which had low serum levels[33]. In contrast, the three main variants within
NOD2/CARD15 did not show any differences in IL-22
serum levels[33]. Although, the exact function of IL-22
in human IBD is still unknown, recent studies have observed increased β-defensin-2 expression and intestinal
epithelial cell migration and proliferation upon stimulation with IL-22[29]. These data ultimately suggests a clinically useful marker to assess disease severity and Th17
cell activity in CD patients[33].
As mentioned above, a rare glutamine allele, rs11209026,
in IL23R conferred protection against CD during a recent genome-wide association study. Recent studies have
proven that this variant protects against CD in both Jewish and non-Jewish populations. In addition, in a study
involving IBD (both UC and CD) patients of Spanish
Caucasian origin, the rs11209026 variant was seen to be
most significantly associated with IBD protection (OR:
0.4; 95% CI: 0.3-0.7)[34]. A study by Dubinsky and colleagues has investigated this rare allele further and how it
protects pediatric CD patients. They used the transmission disequilibrium test (TDT) analysis and genotyping
of whole blood samples from children with IBD and
their two parents. This rare rs11209026 SNP was present
in 2.67% non-Jewish CD patients and 2.94% of non-Jewish UC patients[35]. The TDT demonstrated that the allele
was under-transmitted in all CD offspring and confirmed

WJG|www.wjgnet.com

418

February 7, 2012|Volume 18|Issue 5|

Naser SA� et al . Genetics in Crohn’s disease

This study confirms previously reported findings in CD
patients among North Americans.
In continuation of a study that was described in the
ATG16L section of this paper, Latiano and colleagues
have shown that the replication of IL23R is associated in
adult and pediatric onset of IBD in Italy. Approximately
730 CD patients were genotyped for the rs7517847 and
rs11209026 variants. For the rs7517847 polymorphism,
significant reductions were found in minor allele (G) frequency in CD patients when compared with controls and
in the number of carriers[12]. No differences were found
in UC patients. When the rs11209026 polymorphism
was examined, a significant increase in the frequency of
the risk genotype was observed in CD patients. In either
SNP, there were no correlations between phenotypes of
CD and risk alleles or genotypes of the IL23R gene.
To specify which IL23R variant is the main disease
associated variant, a study using German CD patients
was conducted. Among all 10 IL23R SNPs, they chose
to focus their study on the rs1004819 variant because it
had the strongest association to CD when compared to
controls. This variant showed high prevalence of ileal
involvement when carriers had the TT genotype versus
the CC wild-type genotype[28]. This identification is different from recent data published by Roberts et al[37],
which have identified the rs7517847 variant as having the
strongest association with CD, along with other overlapping North American study populations. They have only
analyzed ileal cases of CD, therefore, it is assumed that
IL23R variants are predisposed to an ileal disease phenotype[37]. In a recent British study, they could not identify
any association between disease phenotype and IL23R
variants[9]. Interestingly, they found that the rs1004819
variant was 1000-fold weaker than that reported in the
German study.
Not only are the IL23R variants highly associated
with CD, they are also associated with other chronic
inflammatory diseases, such as the rs10489629 variant with chronic periodontitis. In psoriasis, the variant rs11209026 has been described as a predisposing
haplotype[17]. In both CD and psoriasis, treatment with
an anti-p40 IL-12/23 antibody has shown promising
results. Antibodies to the p40 subunit block both IL-12
and IL-23, although in knockout mice studies, it has
been proven that IL-23 drives chronic intestinal inflammation[28]. Therefore, IL23R can serve as a therapeutic
target in many different chronic inflammatory diseases,
although the variants may differ among the different
diseases. It is hypothesized that this is due to alternative
mRNA splicing, which results in corresponding IL23R
isoforms with different tissue distribution[28].

ants, SLC22A4 (OCTN1) and SLC22A5 (OCTN2), to CD.
IBD is believed to originate from an uncontrolled mucosal
immunity of the GI tract[17]. Although these variants are
associated with CD, they act independently because there
is no statistical evidence for interaction between IBD5 and
the IL23R, ATG16L1 or CARD15 genes[12].

CTLA4 VARIANTS
The CTLA4 gene is a member of the immunoglobulin
superfamily and is expressed on the surface of helper
T cells. It is located within the 2q33 region, translates
into a protein that plays a role in the immune system,
and may have a genetic association with IBD. It is a
T-cell suppressor, which is essential in the function of
the CD25+ CD4+ regulatory cells[7]. These regulator cells
control the process of intestinal inflammation. Many
SNPs have been studied within this gene and it has been
found that the rs3087243 variant shows the most association with IBD followed by the rs11571302, rs7565213
and rs11571297 variants[35]. Although studies have shown
that the three variants in the CTLA4 gene, g.49A > G
(rs231775), g.-318C > T (rs5742909), and rs3087243,
have no association with CD, other work has suggested
that these variants may control the phenotype of CD[14].
A study performed by Hradsky has shown no crude
association between CD and SNPs within the CTLA4
gene[12]. The study explored the possibility of interactions
in CTLA4 SNPs with variants in IL23R and NOD2. The
R-project package SNPassoc was used and significant
interactions between the three CTLA4 variants with
NOD2 p.Leu1007fsX1008 and IL23R rs11209026 were
observed[12]. This may be due to complex gene-gene interactions. To characterize further the different variants and
whether they determine phenotype in CD patients, the
study used a case-only design. They observed a difference
of minor allele frequency at the rs3087243 gene between
pediatric-onset and adult-onset of CD[12]. It seems that a
genetic factor has a greater impact in early-onset patients
when compared to the adult-onset patients[38]. Within this
study, the age of diagnosis and localization of the disease
was strongly associated with the rs3087243, rs11571302
and rs11571297 variants[12].

NOD2, IL23R, OCTN1/2 AND ATG16L1
POLYMORPHISMS
Gene-gene interactions
Interactions of the major IBD alleles show a high susceptibility in CD patients. Gene-gene interaction can either enhance or weaken the effects of an individual gene,
therefore making it more important than independent
studies looking into the effects of single susceptibility
genes. Csongei and colleagues have performed a genegene interaction analysis in the Hungarian CD population[5]. They concentrated on the two IL23R gene risk
variants (rs2201841 and rs1004819), the ATG16L1 gene
variant (Thr300Ala), and the three NOD2/CARD15

IBD5 GENE
The IBD5 gene is about 250 kb and is located at position
5q31. During a genome-wide linkage analysis, mapping
studies have identified a risk haplotype within the IBD5
locus. Many studies have linked this gene and its two vari-
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variants (rs2066844, L1007fs and rs2066845). Logistic
regression analysis showed that the IL23R variants, both
rs1004819 and rs2201841 and the NOD2/CARD15
variants (rs2066844 and L1007fs) conferred significant
risk for CD. When the patients were homozygous for
IL23R (rs1004819 and rs2201841) variants or ATG16L1,
there was a highly increased risk for CD. When they
analyzed possible statistical interactions between pairs of
ATG16L1, IL23R and CARD15 variants, no evidence
of interactions was found. Therefore, all examined loci
contribute independently to CD risk. Although significant statistical interactions were not detected, these
susceptibility factors may have a cumulative effect in the
Hungarian population.
Further gene-gene interaction studies have been
performed in another population study, as well as assessment of CD genetic risk factors. The study included
five SNP variants for IL23R, the functional variants
SLC22A4 and SLC22A5, and the ATG16L1 mis-sense
risk polymorphism Thr300Ala. All the SNPs, except
for rs1495965 of IL23R, showed significant association
when carriers were either homozygous or heterozygous
for the alleles[2]. Among them all, rs10889677 of IL23R,
showed the strongest association with CD risk[2]. Unsurprisingly, ATG16L1 also showed a strong association
with CD[2]. None of the SNPs showed an association
with UC. When they evaluated correlations between genotype and phenotype for intestinal complications, carriers of the rs7517848 allele of IL23R, particularly those
who were homozygous for the allele, were found to be
at risk for ileal disease. No other SNPs showed differences in genotype or carrier frequencies when compared
to CD patients and their history of complications.
Homozygote variants from the IBD5 and ATG16L1
genes had a greater risk than heterozygotes, suggesting
a gene dosage effect[2]. When SNPs were considered
two at a time, the best interactions were shown between
IL23R_rs10889677 and IBD5_rs17622208, which
were not statistically significant[2]. However, when using a logistic regression approach between these two
markers, the IBD5_rs17622208 risk was only significant in the presence of the IL23R_rs10889677 risk
allele[2]. When SNPs were considered three at a time,
the model suggested statistically significant interactions
between IL23R_rs10889677, IBD5_rs11739135, and
ATG16L1_rs2241880[2]. When SNPs were considered
four at a time, the model suggested interaction between
IL23R_rs2201841, IL23R_rs7517847, and IBD5_
rs11739135[2]. A study in Oxford, UK has hown that
certain IL23R polymorphisms have an association with
CD only when the person is positive for IBD5[2]. In conclusion, the logistic regression model did not show any
significant evidence of gene-gene interaction, due to the
small size of the study, even though there was a consistently small association between IBD5 and IL23R.

The age of childhood and adult onset varies between
cultures to culture because different cultures base it on
different aspects such as physical, mental, or puberty.
North American studies choose an age cut-off of 18
years, and < 18 years is considered a child, even though
an individual at this age is physically mature. This is why
Canadian studies have chosen to describe a child as <
16 years old. The belief is that the lower the age cut-off,
the better the results are when comparing pediatric and
adult onset of disease. Recent studies have shown that
a subgroup of patients with early-onset IBD may have
specific phenotypes that differ from adult-onset IBD[39].
Many believe that pediatric-onset IBD is influenced by
genetics compared to adult onset because there is less
time for exposure to environmental modifiers to influence the onset of disease. Adult-onset is probably due
to a mixture of genetics and abundant environmental
exposure[25]. For example, smoking is a major variable in
adult IBD patients, but has little influence on pediatric
IBD cohorts. Currently, there are conflicting studies on
whether NOD2/CARD15 polymorphisms are associated with the age of onset of IBD because some show
an association towards a younger age, while others show
no effect[40].
A study by Gazouli et al[25] has investigated the main
polymorphisms and their association with childhoodonset of CD in a Greek cohort. While investigating the
genotype and allele frequencies of the NOD2/CARD15
polymorphisms, rs2066844, rs2066845 and 3020insC,
a statistically significant association between rs2066844
and adult-onset CD was observed. In both pediatric- and
adult-onset CD, individuals with at least one NOD2/
CARD15 polymorphism showed a genotype-phenotype
correlation with ileal involvement[25]. The study also confirmed the recently described association between IL23R
variants in both child- and adult-onset CD [35]. There
has been conflicting evidence in studies regarding the
ATG16L1 SNPs. One study has shown no association
with early-onset or adult-onset CD[25]. Recent research
has indicated that the ATG16L1 rs2144880 variant is
associated with adult-pediatric-onset CD, whereas other
studies have demonstrated an association with diagnosis
at an earlier age[25]. In conclusion, the 3020insC variant
in the NOD2/CARD15 gene is associated with CD and
occurs considerably more often in childhood- than in
adult-onset patients with CD[25].
There is growing evidence that pediatric-onset IBD
shows distinct differences when compared to its adult
counterpart. Familial aggregation studies have shown an
age-adjusted risk of developing IBD in first-degree relatives of affected individuals compared to the general population[23]. The risk increases to > 30% for children when
both parents are affected with IBD, suggesting that family history is the strongest risk factor[5]. This is especially
true among CD patients. Familial cases of CD occur at a
younger age with greater severity than random sporadic
cases[36]. One main difference observed between pediatricand adult-onset is that early onset shows a distinct and

Childhood- vs adult-onset CD
The pathogenesis of pediatric and adult IBD differ.
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more aggressive phenotype, such as the need for surgery,
than similar IBD in individuals > 20 years old[41].
Although NOD2/CARD15 mutations are neither
sufficient nor necessary for the development of IBD,
they are associated with a younger age of onset, presence of ileal involvement, and the development of
strictures[23]. There is also a gene dosage effect for CD
location and complications. For example, stricture complications occur more frequently in CD children with the
1007fs mutation in the NOD2/CARD15 gene compared
to children without this variant due to early surgery[42].
Therefore, children with this mutation have a sixfold increased risk for developing a stricture complication[23].
There has been conflicting evidence among studies
that have attempted to show a link between the IBD5 locus and early-onset CD. A study by Rioux has found that
the IBD5 locus is associated with early-onset CD where
children were defined with an age of onset of < 16 years
old[23]. However, studies from pediatric-onset CD cohorts have demonstrated that the risk of IBD5 is lower
compared to that in adult-onset CD, while others have
demonstrated enhanced risk of developing CD when an
individual has both SLC22A4-A5 and NOD2/CARD15
mutations[43]. This connection may be due to a common
pathophysiological mechanism[23].
Although there is no sex difference among patients
with adult-onset IBD, there is a clear and distinct difference among children with CD. Many studies from
pediatric CD cohorts in the United States, Canada and
the United Kingdom have shown an increase in male incidence. The higher male to female ratio continues to be
unexplained. These differences are not observed among
UC pediatric patients [23]. It seems that sex is an agedependent variable that has more influence on children
than adults with IBD.
There are also phenotypic differences, such as disease
location, among children and adult CD. For example, increased rates of upper GI tract disease and pure colonic
disease in pediatric-onset CD have been identified. This
difference may be due to the amount of examination
during the onset of disease. Children undergo extensive
GI endoscopy, whereas adults do not[23]. These findings
may be artificial or represent a true disease distinction
among children and adults. Another distinction is the
occurrence of colon-predominant disease during childhood-onset IBD under the age of 10 years old. With
children < 5 years old, all have colon-only disease[44].
During a study of approximately 1400 North American
early-onset patients, data showed a colon-predominant
phenotype in children < 8 years old. In another study in
Europe, the acquisition of ileal CD became increasingly
common as an individual approached 16 years old[23].
These data confirm an association of colon-predominant phenotype in early diagnosed children that changes
as they grow older.

ied in a Lithuanian cohort with IBD. The study included
57 unrelated patients with CD, 123 with UC and 186
healthy individuals as controls. The three NOD2 variants, the IL23R variant rs11209026, and the ATG16L1
variant Thr300Ala, were genotyped among the population sample. No individuals were carriers of all three
NOD2 risk alleles, whereas two CD patients were compound heterozygotes[10]. Carriers of at least one NOD2
variant were highest among CD patients[10]. There were
no significant differences observed between UC patients
and the controls. The NOD2 variant, Leu1007insC,
was significantly associated with increased susceptibility in the Lithuanian CD population[10]. In comparison
to the other two NOD2 variants, the frequencies were
very low and not significant in controls and among the
IBD patients[10]. In contrast to other European studies, a
positive association between rs2066844, rs2066845 and
CD was not found[10]. When they further tried to analyze
IL23R and ATG16L1, they were unable to replicate previous findings of increased susceptibility to IBD within
the Lithuanian population[10]. They were was a trend for
a possible association with the ATG16L1 risk allele[10]. It
is of particular interest to study this population because
Baltic countries have low IBD incidence rates, especially
for CD. To confirm distinct IBD subtypes, a study using
a larger North-Eastern European IBD sample needs to
be investigated.
Another population study was performed among
New Zealand Caucasians with IBD. Their cohort included 466 UC patients, 496 CD patients and 591
controls. All individuals were genotyped for the IL23R
rs11209026 SNP, the ATG16L1 rs2241880 SNP, and the
CARD15 variants. Significant interaction was detected
between variants in ATG16L1, IL23R and CARD15
and CD susceptibility, whereas no significant association
was observed between IL23R or ATG16L1 genotypes
and IBD sub-phenotypes[37]. The strongest association
occurred between the ATG16L1 rs2241880 variant and
CD, with no association detected with UC[37]. ATG16L1
is suggested to have a CD-specific susceptibility locus.
Unlike ATG16L1, the IL23R rs11209026 variant was
strongly associated with both CD and UC. In their
patient cohort, there was no evidence that IL23R or
ATG16L1 genotypes influenced disease behavior, age
of onset, location, or the need for surgical bowel resection[37]. On the other hand, CARD15 was consistently
a susceptibility factor and predictor of CD phenotype.
Similar to many other studies, all three CARD15 SNPs
are significantly overrepresented in patients with IBD
family history, early onset of disease, ileal disease involvement, and development of complications[33].
Interactions between NOD2 and IL23R variants with tolllike receptor-9 polymorphisms
Toll-like receptors (TLRs) are single, membrane-spanning proteins that play a key role in the innate immune
system. These receptors recognize microbes that have
structurally conserved molecules that breach the physical

Population studies with NOD2, IL23R and ATG16LI
polymorphisms
NOD2, IL23R and ATG16L1 polymorphisms were stud-
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Table 1 Key gene polymorphisms and their significance in Crohn’s disease
Gene

Polymorphism

ATG16L
NOD2/CARD15
IBD5
CTLA4
TNFSF15
IL23R

rs2241880
Thr300Ala
rs2066844, rs2066845, 3020insC, 1007fs
SLC22A4 (OCTN1), SLC22A5 (OCTN2)
rs3087243, rs11571302, rs11571297, rs7565213
80 000 SNPs tested, including 7 SNPs
within a 280 kb region on chromosome 9q32
rs11209026
rs1004819

Relationship significance

Ref.

Associated with ileal form of CD with or without colonic involvement
Highly associated with CD
Independently associated with CD
Independently associated with CD
Associated with IBD; no crude association to CD
Strongly associated with CD for Japanese and Jewish cohorts,
but not for Europeans
Strongly associated with conferring protection against CD
Highly associated with CD

[4,12]
[20]
[12]
[35]
[4,15,16]
[4,33]

SNPs: Single-nucleotide polymorphism; CD: Crohn’s disease.

barriers. Once bound, TLRs activate the immune system.
The responsiveness of the GI tract to luminal bacteria is
dependent on the interaction of transmembrane TLRs
and the intracellular NOD2 receptor [18]. Specifically,
TLR9 plays a role in the maintenance of intestinal inflammation in IBD. TLR9 is also responsible for stimulating NOD2, which in turn enhances innate immune
responses. Patients with two NOD2 mutations lose the
synergistic affect between NOD2 and TLR9 stimulation.
Therefore, interactions of both receptors have implications for intestinal homeostasis and inflammation[18]. The
TLR9 gene is located on chromosome 3p21.3, which
is close to other CD susceptible loci[9]. There are four
SNPs in TLR9, but two of them are sufficient to distinguish between the haplotypes, which are rs5743836 and
rs352140.
There might be a synergistic effect of NOD2 and
TLR9 stimulation, therefore, Torok and colleagues have
tested for gene interactions between TLR9 and CDassociated variants of NOD2[18]. Significant associations
between the two were observed that were specific to
CD[18]. The controls and UC showed no difference in
distribution of TLR9 polymorphisms and NOD2 variants [18]. Other CD variants in IL23R, ATG16L1 and
IBD5 were analyzed for epistatic interactions. Aside
from NOD2, the most significant association was found
in the IL23R variant rs1004819, with ATG16L1 showing
weaker associations with CD. There was no significant
association between TLR9 polymorphisms with CD or
UC phenotypes[18]. Along with previous studies, they
also showed that NOD2 mutations were associated with
younger age of diagnosis of CD, ileal disease, and need
for surgery[18]. When there were two NOD2 mutations,
there was a higher frequency of penetrating disease[18].
In conclusion, a new association between CD and a
TLR9 polymorphism has been found. There is evidence
that when CD patients carry CD-associated NOD2
variants, they have an increased incidence of TLR9
polymorphisms. This is not surprising because there
is a synergistic effect of NOD2 and TLR9 stimulation
and it is important for the maintenance of intestinal
homeostasis and inflammation. TLR9 also demonstrates
significant epistatic interactions with IL23R variants, but
unlike NOD2, there is no association with the frequency

WJG|www.wjgnet.com

in TLR9 polymorphisms present. This study shows the
first evidence for interaction between polymorphisms in
TLR9 and variants between NOD2 and IL23R[18].

CONCLUSION
CD is an autoimmune disease characteristic of chronic
intestinal inflammation and lesions. It can affect people
of all ages and ethnicities worldwide. Recent genomewide studies have shown significant genetic associations
of several variants and susceptibility to CD. This is true
for North American, South American and European
populations. Certain variants have been linked only to
Asian and African cohorts. It is vital to understand the
pathology of CD and the underlying genetic interactions
to increase efficiency of diagnosis and develop drugs
that target specific immune system pathways. There have
been several genetic variants highly associated with CD,
which include ATG16L1, TNFSF15, NOD2/CARD15,
IL23R and IBD5 (Table 1).
The process of autophagy is an important aspect of
our immune system. It is a way to destroy foreign pathogens that enter the body. The Thr300Ala variant within
the N terminus of ATG16L, which is part of a complex
that forms autophagosomes, has significant associations
with CD. Different ethnicities show different genotype
markers. This is seen in TNFSF15, which is involved
in systemic inflammation and regulation of various immune cells. Seven haplotypes have been identified within
a Japanese cohort, but not in other ethnic cohorts. More
research needs to be conducted to characterize fully this
possible genetic link to CD. The most significant association with CD is observed among NOD2/CARD15
and IL23R variants. NOD/CARD15 plays an essential
role in maintaining the intestinal normal flora. There are
many theories about the cause of CD, and one of them
includes a shift in the intestinal bacterial flora. Therefore, it is no surprise that NOD2 variants are highly associated with CD. There are three independent variants
associated with CD: rs2066844, rs2066845 and 1007fs.
The other highly associated genetic link is observed
within the IL23R gene. One variant that is highly associated with CD is rs1004819, whereas rs11209026 confers
protection against CD. IL23R plays an essential role in
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mediating proinflammatory activities. Another highly associated genetic link with CD is observed in two variants
within IBD5. The two variants, SLC22A4 (OCTN1) and
SLC22A5 (OCTN2), show significant association with
CD, but no interactions between these variants and other
CD-associated genetic variants have been observed. The
last highly associated genetic link with CD is observed
within the CTLA4 gene. This gene plays a role in the
immune system. The four polymorphisms associated
with IBD are rs3087243, rs11571302, rs7565213 and
rs11571297.
Many CD variants are associated with a specific CD
phenotype, age of diagnosis, severity and location of
CD, and surgical outcome. Gene-gene interactions have
also been characterized among the different variants and
other immune system receptors. We need to understand
fully the pathogenesis of CD to target pathways for effective treatment. Further research is needed to explore
all possible gene-gene interactions due to a gene dose
affect associated with CD. It seems that new genetic associations are constantly being uncovered within IBD
and then associated with either CD or UC. Overall, CD
shows a greater genetic link than UC. Recent discoveries have led to therapies and treatments that show much
promise. Researchers need to continue the search for
genetic links and diseases because this may be the only
way to understand the pathology of CD and develop effective treatments.
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